The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features.
Romualdo Barroso-Sousa
No relevant relationships to disclose
Rodrigo Ramella Munhoz
No relevant relationships to disclose
Leonardo Gomes Fonseca
No relevant relationships to disclose
Angelo Bezerra de Sousa Fede
No relevant relationships to disclose
Rudinei Diogo Marques Linck
No relevant relationships to disclose
Camila Motta Venchiarutti Moniz
No relevant relationships to disclose
Milena Perez Mak
No relevant relationships to disclose
Ciro Eduardo Souza
Consultant or Advisory Role - Pfizer
Expert Testimony - Pfizer
Paulo M. Hoff
No relevant relationships to disclose
Carlos Dzik
No relevant relationships to disclose